4/27
04:30 pm
clls
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
Low
Report
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
4/14
08:44 am
clls
Cellectis (CLLS) had its "market outperform" rating reaffirmed by Citizens Jmp. They now have a $8.00 price target on the stock.
Low
Report
Cellectis (CLLS) had its "market outperform" rating reaffirmed by Citizens Jmp. They now have a $8.00 price target on the stock.
4/13
04:30 pm
clls
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
Medium
Report
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
3/20
01:08 pm
clls
Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Neutral
Report
Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/19
08:22 pm
clls
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]
Medium
Report
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]
3/19
01:08 am
clls
Cellectis Q4 2025 Earnings Preview [Seeking Alpha]
Low
Report
Cellectis Q4 2025 Earnings Preview [Seeking Alpha]
3/12
04:32 pm
clls
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 [Yahoo! Finance]
Low
Report
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 [Yahoo! Finance]
3/12
04:30 pm
clls
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Low
Report
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
2/17
08:42 am
clls
Cellectis (NASDAQ:CLLS) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $7.00 price target on the stock.
Medium
Report
Cellectis (NASDAQ:CLLS) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $7.00 price target on the stock.